CRL Charles River Laboratories International, Inc.

Here is how Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]

Charles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook.

Charles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...

Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands […]

On September 8, Charles River Laboratories (NYSE:CRL) said its newly automated cartridge manufacturing suite for Endosafe endotoxin testing had reached full operational capacity in the third quarter, a milestone it had been building toward since the system went fully live in July. The timing matters. Charles River has spent much of 2026 shedding businesses and […]

Riverwater Partners, an investment management company, released its ‘Sustainable Value Strategy’ Q2 2026 investor letter. The letter can be downloaded here. Small-cap stocks achieved their best first-half performance since 1991, with the Russell 2500 Value Index rising 17%, driven by the technology sector. The Sustainable Value Strategy underperformed its benchmark in the second quarter. The shortfall […]

Charles River Laboratories International (CRL) just rolled out rapid cell banking programs built around Next-Generation Sequencing and its Pathoquest acquisition, aiming to shorten development timelines for advanced therapies and strengthen quality and regulatory control. For context, Charles River Laboratories International has seen strong momentum build over the past few months, with a 90-day share price return of 52.25% and a 1-year total shareholder return of 79.42%. These figures point...

PGNY vs. CRL: Which Stock Is the Better Value Option?

Charles River Laboratories International (NYSE:CRL) unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools. The platform is designed to shorten biologics and advanced therapy cell bank lead times for biopharma clients while supporting regulatory readiness. Charles River states that the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The new rapid cell banking and release...

The analyst fair value estimate for Charles River Laboratories International has shifted from US$230.93 to US$282.43, a change of about 22% in the updated work. That move sits against Street commentary that now ranges from targets in the low US$200s to just above US$300. This reflects both renewed optimism around growth execution and ongoing discussion about valuation and timing. As you read on, you will see how this evolving price target story fits into the broader narrative and what signals...

Charles River Laboratories International has introduced rapid cell banking programs that shorten cell bank production timelines by about 40% versus the 20‑week industry standard, integrating rapid microbiological methods and CGMP-compliant Next-Generation Sequencing (NGS) to support faster, higher-quality biologic and advanced therapy development. An interesting aspect of this launch is its alignment with Charles River’s Alternative Methods Advancement Project, which aims to cut reliance on...

Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 3.6% in the afternoon session after the company announced the launch of rapid cell banking programs designed to accelerate release timelines.

What a fantastic six months it’s been for Charles River Laboratories. Shares of the company have skyrocketed 79.5%, hitting $272.74. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Charles River benefits from rising advisory demand, a strong talent base and capital returns. Its competition and higher talent costs pressure margins.

FIGS, APH and MSFT post strong gains as Zacks upgrades and model portfolios spotlight stocks outperforming the broader market.

Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRAI gains from strong advisory demand, a diverse client base and specialist talent, but rising costs and tight liquidity pose risks.

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.

Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...

Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

Investors need to pay close attention to CRL stock based on the movements in the options market lately.

CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.

“I want to roll out my strategy to them so that they know why we’re doing things, why the urgency, what are we trying to accomplish and really what it means to them,” Girshick told me during a recent visit to the Leadership Institute’s offices. It’s just one way an ultimate insider is in some ways acting as if she’s an outsider in her quest to transform Charles River which provides drug-development services. Girshick, who started at Charles River as an executive assistant in her home country of Germany, is just the third CEO in the company’s nearly 80-year history and the first unrelated to the founder.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as

Organic revenue returned to growth as biopharmaceutical demand strengthened.

CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.

Charles River Laboratories International (NYSE:CRL) reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earning

In August 2026, Charles River Laboratories International reported second-quarter revenue of US$1,004.08 million, swinging to a small net loss, and simultaneously cut its 2026 GAAP EPS guidance to US$3.05–US$3.35 per share, largely due to losses tied to recent divestitures. Despite these GAAP headwinds, the company exceeded non-GAAP earnings expectations, raised its full-year adjusted EPS outlook, and highlighted strong momentum in its Discovery and Safety Assessment segment, pointing to...

Moby summary of Charles River Laboratories International, Inc.'s Q2 2026 earnings call

Charles River Laboratories International Inc (CRL) beats Q2 targets with a 1.19x book-to-bill, portfolio refinements boosting margins, and a new Cambodian NHP supply deal set to drive Q4 gains.

Shares of Charles River Laboratories blew out of a buy zone Wednesday after the medtech company hit its highest book-to-bill ratio in four years.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.

Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.

Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.